A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study)  by Legutko, Jacek et al.
ww.sciencedirect.com
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 3 8 8e3 9 4Available online at wjournal homepage: www.elsevier .com/locate / ih jOriginal ArticleA clinical evaluation of the ProNOVA XR polymer-
free sirolimus eluting coronary stent system in the
treatment of patients with de novo coronary artery
lesions (EURONOVA XR I study)5Jacek Legutko a,b,*, Wojciech Zasada a,d, Grzegorz L. Kału _za e,
Grzegorz Heba a, Lukasz Rzeszutko a, Jacek Jakala a, Jacek Dragan c,
Artur Klecha b, Dawid Giszterowicz c, Wojciech Dobrowolski c,
Łukasz Partyka d, Swaminathan Jayaraman f, Dariusz Dudek aaDepartment of Interventional Cardiology, Jagiellonian University, Krakow, Poland
bDepartment of Invasive Cardiology, Electrotherapy and Angiology, Intercard, Nowy Targ, Poland
cDepartment of Invasive Cardiology, Electrotherapy and Angiology, Intercard, Nowy Sa˛cz, Poland
dKrakow Cardiovascular Research Institute, Krakow, Poland
eCardiovascular Research Foundation, New York, NY, USA
fVascular Concepts Limited, UKa r t i c l e i n f o
Article history:
Received 23 April 2013
Accepted 28 June 2013
Available online 21 July 2013
Keywords:
DES
IVUS
QCAAbbreviations: PF, polymer-free; EEM, exte
5 Clinical Study was performed in Departm
Invasive Cardiology, Electrotherapy and Ang
and Angiology, Intercard, Nowy Sa˛cz, Poland
* Corresponding author. Institute of Cardiology
fax: þ48 12 424 71 84.
E-mail address: jlegutko@kcri.org (J. Legu
0019-4832/$ e see front matter Copyright ª
http://dx.doi.org/10.1016/j.ihj.2013.06.026a b s t r a c t
Aims: Evaluation of safety and efficacy of ProNOVA XR, a new generation of polymer-free
sirolimus eluting stents (SES), utilizing a pharmaceutical excipient for timed release of
sirolimus from the XR platform.
Methods and results: Safety and efficacy of ProNOVA XR coronary stent system was exam-
ined in EURONOVA prospective, single arm, multi-center registry of 50 patients with de
novo native coronary lesions up to 28 mm in length in arteries between 2.25 and 4 mm.
At 6-month, in-stent late lumen loss by QCAwas 0.45 0.41mm and in-stent neointimal
volume obstruction in the IVUS sub-study was 14  11%. One-year clinical follow-up
revealed a favorable safety profile, with 2% of in-hospital MACE and 6.4% of MACE from
hospital discharge up to 12 months (including 1 cardiac death >30 days after stent im-
plantation and 2 TLRs). According to the ARC definition, there was no definite or probable
stent thrombosis and 1 possible stent thrombosis (2%) up to 12months of clinical follow-up.
Conclusions: In this preliminary evaluation, ProNOVA XR polymer-free sirolimus eluting stent
system appeared safe with an early promise of adequate effectiveness in the treatment of de
novo coronary lesions in up to 12 months of clinical, angiographic and IVUS follow-up.
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i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 3 8 8e3 9 4 3891. IntroductionFig. 1 e Sirolimus release kinetics of the ProNOVA XR stent.Percutaneous coronary interventions (PCI) with drug eluting
stents (DES) are considered most effective and secure way
of treatment for de novo single vessel coronary artery disease.1
DESs eluting the two most commonly utilized anti-
proliferative medications, paclitaxel and sirolimus, have
shown to be overwhelmingly superior to the baremetal stents
(BMS) in reducing restenosis and target vessel revasculariza-
tion, as proven in multiple randomized trials.2e4 However,
most of currently used DES employ a polymer coating as a
drug carrier, and the permanent presence of these durable
polymers has been associated with increased risk of late and
very late thrombosis and local inflammatory responses.5e7 On
the other hand, the use of bioresorbable polymers has been
most recently shown to be associated with decreased definite
stent thrombosis when compared to durable polymer DES and
lower revascularization rates in bifurcation lesions.8e10
Consequently, these observations have stimulated the devel-
opment of novel stent systems employing biodegradable
polymers as drug carriers, or completely polymer-free DES.11
The ProNOVA XR stent is representative of these new gener-
ation polymer-free sirolimus eluting stents (SES). The aim of
the present Euronova XR I study was a preliminary assess-
ment of the safety and efficacy of the ProNOVA XR Polymer-
Free Drug Eluting Stent System in the treatment of consecu-
tive patients with de novo coronary artery lesions in the
real-world use setting.2. Methods
2.1. Device description
The XR Stent platform is manufactured from an L605 cobalt-
chromium alloy, with 65-micron thin stent struts and
employs a pharmaceutical excipient e polylactic glycolic acid
(PLGA) e for the timed release delivery of sirolimus from the
XR stent platform. The formulation of PLGA used in the Pro-
NOVAXR stent was tailored such that the polymer is absorbed
once the drug release is completed. Hence the stent is poly-
mer-free upon release of the drug, which is maintained uni-
formly up to 30 days and after this time less than 25% of the
drug remains on the surface of the stent. The release kinetic is
presented in Fig. 1.
2.2. Study design and Patient population
EURONOVA XR I Study was a prospective, single arm, multi-
center registry evaluating performance, safety and efficacy of
the ProNOVA XR DES in the real-world use setting. A total of
consecutive 50 patients with de novo native coronary artery
lesions, who were admitted for PCI at 4 investigational sites in
Poland, were enrolled in the study. This study was conducted
in accordance with Declaration of Helsinki and the protocol
approval was obtained from the Local Ethics Committee of the
Jagiellonian University, Krakow, Poland (Principal In-
vestigator’s site). The study was registered in NCT
(NCT01151033).Patients older than 18 years of age, with de novo lesions (no
prior stent implant; no brachytherapy), with reference vessel
diameter between 2.25 mm and 4.0 mm and target lesion
28 mm in length assessed by visual estimate and with evi-
dence of myocardial ischemia (e.g. stable or unstable angina,
silent ischemia) were eligible for inclusion provided that
written informed consent prior to any study related procedure
was obtained from the patient or the patient’s legally autho-
rized representative. Exclusion criteria were: other medical
illnesses, known history of substance abuse, limited life ex-
pectancy <1 year, contraindications to dual antiplatelet
therapy, participation in another study, nursing or pregnancy.
2.3. Procedure and medications
Procedural success was defined as successful delivery and
deployment of the study stent at the intended target lesion
and successful withdrawal of the stent delivery system with
attainment of final residual stenosis of less than 50% of the
target lesion by QCA (or by visual estimate if QCA was
unavailable), without use of a device outside the assigned
treatment strategy and without adverse cardiovascular
events.
Patients were pretreated with loading doses of aspirin
(75 mg) and clopidogrel (300 mg), between 12 and 6 h prior
to the index procedure if possible, followed by maintenance
dosages of clopidogrel (75 mg daily) for a minimum of one-
year and aspirin (75mg daily) for aminimumof 5 years. Either
unfractionated heparin or bivalirudin were used for proce-
dural anticoagulation. The use of glycoprotein IIb/IIIa in-
hibitors was left to the discretion of the investigator.
2.4. Data collection and core laboratory analyses
All data were submitted to the independent core laboratory
(KCRI, Krakow, Poland). The core laboratorywas blinded to the
clinical data and procedural information.
Coronary angiograms, obtained at baseline, immediately
after the procedure, and at follow-up were digitally recorded
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 3 8 8e3 9 4390and assessed Sanders Data Systems QCAPlus software (Palo
Alto, CA, USA). Measurements were performed on the angio-
grams after maximum vasodilatation with nitroglycerin and
the average of multiple projections were analyzed with the
help of an automated edge-detection system. The contrast-
filled, non-tapered catheter tip was used for calibration (6
French guiding catheter).
All angiographic measurements of the target lesion were
obtained in the “in-stent” zone, within 5 mm proximal and
distal margins to each stent edge, and over the entire segment
(“in-segment” zone). Quantitative QCA parameters included
the reference vessel diameter (RVD), minimal luminal diam-
eter (MLD), percent diameter stenosis (difference between
reference vessel diameter and minimal luminal diameter/
reference diameter 100), and late lumen loss (LLL, difference
between minimal luminal diameter after the procedure and
minimal luminal diameter at follow-up). Binary restenosis
was defined as stenosis of 50% or greater of the minimal
luminal diameter in the target lesion.
Intravascular ultrasonographic (IVUS) sub-study included
33 of the 50 enrolled patients. IVUS examinations were per-
formed after stent implantation and at follow-up using the
commercially available Atlantis SR Pro Imaging Catheter
(Boston Scientific, Natick, MA, USA). Quantitative analysis,
according to the guidelines of the American College of Cardi-
ology (ACC) was performed off-line by two experienced ana-
lysts using a dedicated software package echoPlaque 3 (Indec
Medical Systems, Santa Clara, CA, USA).12
Quantitative measures obtained every 0.5 mm of the stent
length included the external elastic membrane (EEM) (mm2),
lumen cross-sectional area (CSA) (mm2), and stent CSA (mm2)
in the stented and 5 mm proximal and distal reference seg-
ments. Incomplete stent apposition (ISA) was defined as the
lack of contact between at least 1 strut and the underlying
arterial wall intima that did not overlap a side branch with
evidence of blood flow behind the strut. Stent malapposition
was defined as a separation of at least 1 stent strut not in
contact with the intimal surface of the arterial wall that was
not overlapping a side branch, was not present immediately
after stent implantation, and had evidence of blood speckling
behind the strut.13 Stent expansion index was defined as the
ratio of minimal stent CSA divided by the mean proximal and
distal reference lumen areas. Stent underexpansion was
defined as stent expansion <80% (stent expansion index
<0.80). Neointimal area was calculated as stent area minus
lumen area. Volumes were calculated by assuming a 0.5 mm
thickness of each cross-section with no change in planimetric
measurements within that 0.5 mm thickness, and adding the
consecutive slices to obtain the volume over the entire stent
length.
2.5. Follow-up
Clinical evaluation was scheduled at 1, 6, and 12 months with
assessment of angina status, collection of data regarding
adverse events, and use of concomitant medications. Follow-
up angiography was performed at 6 months. IVUS imaging
was obtaining at the 6-month follow-up of 33 patients
enrolled to IVUS sub-study. Patients were enrolled to IVUS
sub-study in all centers where IVUS imaging was available.2.6. Study endpoints
The primary endpoint of the study was angiographic in-stent
LLL at 6 months after stent implantation. The secondary
clinical endpoints were: device success, lesion success, pro-
cedural success and assessed at 30 days, 6 and 12 months,
target lesion revascularization (TLR), target vessel revascu-
larization (TVR), cardiac death, all deaths (cardiac and non-
cardiac), myocardial infarction (Q-wave and non Q-wave),
definite, probable, and possible stent thrombosis and occur-
rence of MACE (defined as composite of death, MI and TLR) or
MACCE (defined as composite of cardiac death, MI and TLR).
Secondary angiographic endpoints assessed at 6 months
follow-up by QCA were: in-stent and in-segment percent
diameter stenosis (% DS), in-stent and in-segment binary
restenosis rate, in-stent and in-segmentMLD. Secondary IVUS
endpoints from IVUS sub-study assessed at 6 months follow-
up were: in-stent and in-segment LLL, in-stent neointimal
volume obstruction, rate of incomplete stent apposition.2.7. Statistical analysis
Continuous variables were presented as means and stan-
dard deviations. A probability <0.05 was considered to be
statistically significant. Statistical analysis was performed
using the JMP software, version 9.0.0 (SAS Institute Cary, NC,
USA).
For angiographic parameters, one sided paired t-test or
Wilcoxon signed-rank test (depending on normality) was
used. Because measurements were dependent and direction
of difference was known, only the significance of observed
differences was investigated.
The primary endpoint and all study endpoints were
analyzed on the per-treatment evaluable population (patients
who had nomajor protocol deviations). Patients lost to follow-
up were not included in the denominator for calculations of
binary endpoints.3. Results
3.1. Procedural results and angiographic outcomes
A total of 50 study patients were randomized and enrolled at
4 investigational sites between January 2009 and February
2010. The demographic characteristics of patients enrolled to
Euronova XR I Study are shown in Table 1. Patient flow in the
study is presented in Fig. 2. Procedure success was achieved in
49 patients (98%; one patient had clinically indicated in-
hospital TLR).
Results of QCA are shown in Tables 2 and 3. The primary
endpoint of the study was an angiographic in-stent LLL at 6
months after stent implantation, which was 0.45  0.41 mm.
In-stent binary restenosis was observed in 4.1% of the treated
lesions. By IVUS, in 33 patients enrolled to IVUS sub-study, in-
stent neointimal volume obstruction at 6 months was
14.11 11.45%. Specific information on other IVUS variables is
summarized in Table 4.
Table 1eDemographic characteristic of enrolled patients.
On admission (n ¼ 50)
Age 63.0  9.25 years
Male gender 39 (78%)
Current smokers 14 (28%)
Diabetes 12 (24%)
Hypertension 45 (90%)
Hyperlipidemia 43 (86%)
Prior intervention 34 (68%)
Prior MI 38 (76%)
Stable angina 37 (74%)
Prior PCI 35 (70%)
NSTE ACS 13 (26%)
Table 2 e Baseline QCA and procedural data.
Target vessel n (%)
LAD 23 (44)
Cx 11 (21)
RCA 16 (31)
IM 2 (4)
Lesion class (AHA/ACC)
A 7 (13) 22 (42)
B1 15 (29)
B2 24 (46) 30 (58)
C 6 (12)
Vessel and lesion
Reference vessel diameter (mm; SD) 3.00  0.45
Lesion length (mm; SD) 18.07  9.55
Minimal Luminal Diameter (mm) 1.06  0.38
Diameter stenosis (%) 65.08  11.34
Predilatation (n [ 32)
Balloon length (mm; SD) 16.90  3.27
Balloon diameter (mm; SD) 2.60  0.42
Implantation pressure (atm; SD) 11.80  1.84
Stent
Stent length (mm; SD) 19.76  5.63
Stent diameter (mm; SD) 3.14  0.34
Implantation pressure (atm; SD) 14.29  1.55
No of stents per lesion 1.13
Postdilatation (n [ 36)
Balloon length (mm; SD) 13.60  3.48
Balloon diameter (mm; SD) 3.50  0.43
Implantation pressure (atm; SD) 16.00  3.09
Dissection (all) 8
Type A 4
Type B 4
SB closure 0
Embolization 0
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Clinical follow-up revealed a favorable safety profile, with 2%
of in-hospital MACE (one urgent repeat PCI 24 h after the
procedure due to recurrence of symptoms related to stent
edge dissection) and 6.4% of MACE from hospital discharge up
to 12 months (including 1 cardiac death and 2 TLRs). One pa-
tient was admitted to local hospital 7 months after index
procedure due to exacerbation of heart failure and died
during that hospitalization. Control coronary angiography
was not performed, so this event is classified as possible stent
thrombosis. Two other patients were hospitalized due to un-
stable angina in 5th and 7th month of observation and both of
them had restenosis in study stent diagnosed in control cor-
onarography and treated by PCI procedure. Detailed infor-
mation regarding one-year clinical follow-up is presented in
Table 5.
A typical case example is shown in Fig. 3. There is an
evident LAD lesion in angiography (1) treated by ProNOVAFig. 2 e Patient flow in the study.stent (angiographic and IVUS post-implant results 2, 2a) and
seen again at follow-up with favorable outcome (3, 3a, 3b, 3c).4. Discussion
This study aimed at establishing a preliminary safety and ef-
ficacy profile of a novel polymer-free sirolimus eluting stent
ProNOVA XR. In a prospective 4-center registry of patients
with de novo lesions followed-up angiographically at 6 months
and clinically until 12 months, standard indices of safety and
efficacy suggested a favorable response to the new device. The
study’s primary endpoint of LLL was 0.45  0.41 mm. This
represents a reduction from the typical LLL in the bare metal
stents, as exemplified by the SIRIUS pivotal trial of the siroli-
mus eluting stent (Cypher) which showed 1.00  0.70 mm LLL
in the control arm.14 Such in-stent LLL is comparable to that
reported across different studies of paclitaxel-eluting stents in
the total of 2692 patients (0.40 mm) in a recent meta-
analysis.15 It also appears somewhat lower than the average
calculated for the zotarolimus-eluting stents (0.56 mm), and
similar to that reported in the “other” category (0.46 mm) in
the samemeta-analysis (this category consisted of pooled 919
patients whowere treatedwith Yukon polymer-free sirolimus
containing stent), with or without estrogen coating, biode-
gradable sirolimus polymer stent and Costar (absorbable
polymer eluting paclitaxel).
Table 4 e IVUS outcomes.
Baseline (n ¼ 33) 6-Month follow-up (n ¼ 33) p ¼
Vessel volume (mm3) 300.7  119.9 322.5  128.6 0.48
Stent volume (mm3) 136.8  49.0 146.8  52.1 0.43
Luminal volume (mm3) 136.8  49.0 127.8  48.0 0.46
In-stent neo-intimal volume (mm3) e 20.4  15.9 e
In-stent volume obstruction (%) e 14.11  11.45 e
LA mean ref. proks. (mm2) 8.24  3.31 7.91  2.75 0.51
LA mean ref dist (mm2) 5.94  1.89 6.26  2.06 0.79
MLA in-stent (mm2) 5.45  1.46 4.68  1.41 0.03
MLA in-stent <5.5 mm2 (n ¼, %) n ¼ 6, 18.1% e e
Stent expansion ratio 0.81 e e
% Stent expansion <80% (n ¼ , %) n ¼ 5, 15.2% e e
%PB ref. proks. (%) 48.42  11.15 50.21  10.00
%PB ref. dist (%) 39.81  13.50 38.97  12.89
Edge dissection (n ¼, %) n ¼ 3, 9.4% n ¼ 0, 0% 0.07
Acute stent malapposition (%) n ¼ 8, 24.2% n ¼ 6, 18.1% 0.55
Late acquired stent malapposition (%) e n ¼ 5, 15.2% e
Table 3 e Follow-up QCA data.
Proximal edge (n ¼ 47) In-stent (n ¼ 49) Distal edge (n ¼ 49) In-segment (n ¼ 49)
Reference vessel diameter (mm)
After procedure 2.98  0.37 (n ¼ 52)
At 6 m FU 2.93  0.36 (n ¼ 49)
Minimal luminal diameter (mm)
After procedure 2.71  0.45 2.62  0.34 2.33  0.42 2.28  0.39
At 6 m FU 2.38  0.47 2.16  0.39 2.27  0.42 2.01  0.39
p value (one sided paired T-test or
Wilcoxon signed-rank test,
depends on normality)
<0.001 <0.001 0.03396 <0.001
Late loss (mm)
At 6 m FU 0.33  0.36 0.45  0.41 0.06  0.36 0.28  0.45
Diameter stenosis (% DS)
After procedure 10.51  10.11 12.96  9.52 22.86  10.26 24.37  9.42
At 6 m FU 19.04  13.76 26.20  11.74 22.84  11.07 31.67  11.80
p value (one sided paired T-test or
Wilcoxon signed-rank test,
depends on normality)
<0.001 <0.001 0.2852 0.000788
Binary restenosis
At 6 m FU 1/47 (2.1%) 2/49 (4.1%) 0/49 (0%) 3/49 (6.1%)
Table 5 e One-year clinical follow-up.
From admission to
12 month FU (n ¼ 47)
Cardiac death 1 (2.1%)
Myocardial Infarction 0
Reintervention e TLR 2 (4.3%)
Major adverse cardiac events
(defined as: death, myocardial
infarction, TLR)
6.4% (3 e one cardiac
death, two TLR)
Stent thrombosis (ARC)
Definite 0 (0%)
Probable 0 (0%)
Possible 1 (2.1%)
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consistently reported for the durable polymer-based sirolimus
eluting stents such as Cypher, or for newer everolimus-eluting
stents (Xience/Promus), the TLR remained low at 4%. When
events related to the target vessel are summarized, the target
vessel failure (not originally set as an endpoint per protocol)
would be 10.6% (5/47 patients), of which 2 were TLR, two were
TVR and one death which occurred at 197 days in a remote
hospital and based on limited documentationwas adjudicated
as possible stent thrombosis, however, autopsy was not per-
formed. These rates are similar to those reported in the 1-year
follow-up of the SIRIUS trial (TLR 4.9%, target vessel failure
9.8%).16
When compared with other studies of polymer-free siro-
limus eluting stent, the ProNOVA XR appeared similar in
outcomes. Slightly higher LLL was reported for ChoiceDES in
Fig. 3 e Representative case from the study. PCI of a circumflex artery with critical stenosis in proximal segment before
stenting (1), after ProNOVA XR implantation (2 and 2a); and at 6-month angiographic follow-up (3, 3a and 3b).
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subsequent ISAR-TEST 2 (0.23  0.50 mm).18 Hydroxyapatite-
based release of sirolimus from the VESTAsync system
demonstrated LLL of 0.36  0.23 mm.19 However, in terms of
clinical outcomes, the ProNOVA XR stent demonstrated lower
TLR than other investigated polymer-free platforms, 4.2% in
comparison to 9.3% and 6.8% achieved in ISAR-TEST 1 and
ISAR-TEST 2, respectively. Similarly, percentage of in-
segment binary restenosis was lower than in the ISAR
studies e 6.1% for ProNOVA and from 11% up to 14.2% for
ISAR-TEST 2 and 1 respectively. In all these 3 studies, the
investigated population had similar distribution of lesion
types, with noticeable predominance of more complex lesion
(B2 and C over 50%), and the present study featured longer
baseline lesion length than the 3 comparator studies, which is
a predisposing factor for DES restenosis.20
4.1. Limitations of the study
The study was non-randomized, without a control compar-
ator treatment and in a limited number of patients. Also, given
the theoretical benefit of a better artery healing in absence of
permanent polymer coating on our investigative stent, it
would also require a longer follow-up to more adequately
examine the possible positive impact of the particular stent
design on the adverse clinical events such as stent thrombosis
and possibility to shorten the antiplatelet therapy. However, it
is customary for a first-in-man study to have this feasibility
single arm design and expand to larger randomized investi-
gation if the initial results are positive.
In summary, even though the study sample was small,
results of this preliminary study demonstrate that thepolymer-free sirolimus eluting ProNOVA XR stent system is
safe, with outcomes similar to other polymer-free drug eluting
stents. This preliminary assessment encourages further
investigation.Conflicts of interest
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